In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation
Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable Regulatory Agency (United States Food and Drug Administration – FDA), citing a survey in which 82% of biopharma respondents said they were concerned about the FDA’s ability to function.